<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Braunwald, Eugene</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Intensive Lipid-Lowering Therapy with Simvastatin/Ezetimibe Combination Does Not Affect the Progression of Aortic Valve Stenosis: Results from the SEAS Study</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">25-26</style></pages><abstract><style  face="normal" font="default" size="100%">Results from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS; NCT00092677] study indicate that intensive LDL-cholesterol-lowering with the combination of simvastatin 40 mg and ezetimibe 10 mg does not affect the progression of aortic valve stenosis, but can reduce the risk of cardiovascular ischemic events in subjects with mild-to-moderate asymptomatic aortic stenosis, when compared with placebo.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>